LP-118 is a BCL-2/BCL-XL inhibitor that demonstrated efficacy in venetoclax-naive and venetoclax-resistant CLL, primarily through BAK activation and cytochrome C release. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.